Clinical trials: Spinal Cord Diseases
Cancer, Hematologic Malignancies
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone disease from multiple myeloma.
- Conditions
- Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology
- Trial name
- NCT01345019
- Testing
- Denosumab, Zoledronic acid, Denosumab (for the open-label treatment phase)
- Where
- 309 sites in United States, Australia and 27 more
- Volunteers
- 1,718 people
- Sponsor
- Amgen
ALS (Amyotrophic Lateral Sclerosis)
A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate how well LY4256984 is tolerated and what side effects may occur in participants with sporadic amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT07100119
- Testing
- LY4256984
- Where
- 12 sites in Belgium, Canada and 3 more
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Acute Spinal Cord Injury (SCI), Spinal Cord Diseases
NG004 in Spinal Cord Injury Patients
This is the FIH, multicenter, open-label, sequential, multiple ascending dose trial of NG004 in patients with acute incomplete cervical SCI.
- Conditions
- Acute Spinal Cord Injury (SCI), Spinal Cord Diseases, Central Nervous System Diseases, Nervous System Diseases
- Trial name
- SPROUT (NCT06817577)
- Testing
- NG004
- Where
- 6 sites in Germany, Switzerland
- Volunteers
- 20 people
- Sponsor
- NovaGo Therapeutics AG
Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III Non Ambulant
Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.
Assess the efficacy and the safety of olesoxime in SMA type 2 or type 3 non ambulant patients aged 3-25 years
- Trial name
- NCT01302600
- Testing
- Olesoxime
- Where
- 22 sites in Belgium, France and 5 more
- Volunteers
- 165 people
- Sponsor
- Hoffmann-La Roche
Diphtheria, Tetanus
Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants
This study will assess both the antibody persistence of the investigational vaccine and the immune response and safety of a booster dose of PENTAXIM™ vaccine in 18 months-old toddlers who participated in an earlier study in order…
- Conditions
- Diphtheria, Tetanus, Pertussis, Poliomyelitis
- Trial name
- NCT00303316
- Testing
- DTaP-IPV//PRP~T combined vaccine
- Where
- Argentina
- Volunteers
- 458 people, healthy volunteers welcome
- Sponsor
- Sanofi
Spinal Cord Injury, Muscle Spasticity
Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury
Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs.
- Trial name
- NCT00041717
- Testing
- Fampridine-SR
- Where
- 45 sites in United States, Canada
- Volunteers
- 213 people
- Sponsor
- Acorda Therapeutics
Chronic Spinal Cord Injury
A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury
The goal of this clinical trial is to learn if NVG-291 can improve function in adults with chronic cervical motor-incomplete spinal cord injury. It will also learn about the safety of NVG-291.
- Trial name
- RESTORE (NCT07799532)
- Testing
- NVG-291
- Where
- 23 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- NervGen Pharma
Spinal Muscular Atrophy
A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy
This is a multi-center, exploratory, non-comparative, and open-label study to investigate the safety, tolerability, PK, and PK/PD relationship of risdiplam in adults, children and infants with Spinal Muscular Atrophy (SMA)…
- Trial name
- Jewelfish (NCT03032172)
- Testing
- Risdiplam
- Where
- 24 sites in United States, Belgium and 7 more
- Volunteers
- 174 people
- Sponsor
- Hoffmann-La Roche
Cervical Spinal Cord Injury, Spine Injury
Dose Escalation Study of AST-OPC1 in Spinal Cord Injury
The purpose of this study is to evaluate the safety of cross sequential escalating doses of AST-OPC1 administered among 5 cohorts at a single time-point between 21 and 42 days post injury, inclusively, to subjects with subacute…
- Conditions
- Cervical Spinal Cord Injury, Spine Injury, Spinal Cord Trauma
- Trial name
- NCT02302157
- Testing
- AST-OPC1
- Where
- 9 sites in United States
- Volunteers
- 25 people
- Sponsor
- Lineage Cell Therapeutics, Inc.
Spinal Cord Injury
Safety and Efficacy of SC0806 (Fibroblast Growth Factor 1 and a Device) in Traumatic Spinal Cord Injury Subjects
This is an open, randomized, rehabilitation-controlled study in subjects with complete Traumatic Spinal Cord Injury, where the active treatment consists of a surgical implantation of SC0806 (a biodegradable device with…
- Trial name
- NCT02490501
- Testing
- SC0806 and rehabilitation, Rehabilitation only
- Where
- Sweden
- Volunteers
- 10 people
- Sponsor
- BioArctic AB
Spinal Cord Injuries, Gait Disorders, Neurologic
Safety and Feasibility of TWIICE Rise
The aim of this study is to assess the safety and the feasibility of two versions of TWIICE Rise for exoskeleton-assisted ambulation in patients with a spinal cord injury.
- Trial name
- NCT05926310
- Testing
- TWIICE Rise
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- TWIICE
Neurologic Disorder, Paralysis
EMPOWER Early Feasibility Study: Non-invasive BCI to Control a Wheelchair for People With Paralysis
Neuralis is an innovative assistive technology designed for individuals with severe neuromuscular conditions, enabling wheelchair control through EEG signals.
- Conditions
- Neurologic Disorder, Paralysis, Paralysis; Stroke, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06169696
- Testing
- Intervention/Treatment
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Synaptrix Labs Inc.
Androgenetic Alopecia
Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia
Previous studies of finasteride treatment in women with hair loss have failed to show positive results, yet, some women have responded anecdotally.
- Trial name
- NCT01052870
- Testing
- Finasteride
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- HairDx, LLC
Poliomyelitis
A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants
The purpose of this phrase III clinical trial is to evaluate the immunogenicity and safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) in a '1+2' sequential schedule with bivalent oral poliovirus vaccine in 2-month-old…
- Trial name
- NCT03822754
- Testing
- sIPV-bOPV-bOPV vaccination schedule, wIPV-bOPV-bOPV vaccination schedule
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Diphtheria, Tetanus
Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months
As per request by the Heath Authorities, the present clinical study will assess the immunogenicity and safety of sanofi pasteur's DTacP-IPV// PRP~T combined vaccine (PENTAXIM™) as a three-dose primary vaccination at 2, 3, and 4…
- Conditions
- Diphtheria, Tetanus, Haemophilus Influenzae Type b, Pertussis
- Trial name
- NCT00453570
- Testing
- Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib, Diphtheria, Tetanus, & Acellular Pertussis Combined, Absorbed
- Where
- China
- Volunteers
- 792 people, healthy volunteers welcome
- Sponsor
- Sanofi
Sialorrhea
Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects
This study will evaluate the efficacy and safety of MYOBLOC in the treatment of Sialorrhea (drooling), which can be a symptom of many disease conditions. MYOBLOC will be injected directly into the salivary glands.
- Trial name
- MYSTICOL (NCT01994109)
- Testing
- MYOBLOC
- Where
- 34 sites in United States, Russia and 1 more
- Volunteers
- 187 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Acquired Brain Injury (Including Stroke), Spinal Cord Injury
Clinical Investigation to Validate the Safety and Performance of Integrating Functional Electrical Stimulation Into the ABLE Exoskeleton
The primary objective of this study is to validate the safety and clinical performance of the ABLE Exoskeleton with integrated Functional Electrical Stimulation (ABLE FES) in individuals with neurological conditions that impair…
- Conditions
- Acquired Brain Injury (Including Stroke), Spinal Cord Injury, Multiple Sclerosis
- Trial name
- NCT07550699
- Testing
- ABLE Exoskeleton with Functional Electrical Stimulation (ABLE FES)
- Where
- Austria
- Volunteers
- 14 people
- Sponsor
- ABLE Human Motion S.L.
Degenerative Disc Disease
Study of Posterior Cervical Stabilization System (PCSS) as Part of Circumferential Fusion to Treat Multilevel DDD
This study will evaluate the safety and effectiveness of a device called "Posterior Cervical Stabilization System or PCSS" when used along with posterior cervical fusion (PCF) in combination with anterior cervical discectomy and…
- Trial name
- FUSE (NCT04229017)
- Testing
- Anterior Cervical Discectomy and Fusion, Posterior Cervical Stabilization System (PCSS)
- Where
- 17 sites in United States
- Volunteers
- 236 people
- Sponsor
- Providence Medical Technology, Inc.
Spinocerebellar Degeneration
An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
The purpose of this study is to evaluate the long-term safety, efficacy, and pharmacokinetics of KPS-0373 in SCD patients.
- Trial name
- NCT01970111
- Testing
- KPS-0373, High dose, KPS-0373, Low dose
- Where
- Japan
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND
Multicenter, open-label , single and multiple dose-escalation and pharmacokinetic study
- Trial name
- NCT02870634
- Testing
- Cu(II)ATSM
- Where
- 2 sites in Australia
- Volunteers
- 50 people
- Sponsor
- Collaborative Medicinal Development Pty Limited